163 related articles for article (PubMed ID: 25385179)
1. Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Muss HB
Breast Cancer Res Treat; 2015 Jan; 149(2):321-30. PubMed ID: 25385179
[TBL] [Abstract][Full Text] [Related]
2. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Tamura K
Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
[TBL] [Abstract][Full Text] [Related]
3. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
4. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
Drucker AM; Wu S; Dang CT; Lacouture ME
Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
9. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
10. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
13. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
[TBL] [Abstract][Full Text] [Related]
14. Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.
Li H; Fu W; Gao X; Xu Q; Wu H; Tan W
Tumour Biol; 2014 May; 35(5):4077-85. PubMed ID: 24375251
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
16. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
17. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Swain SM; Schneeweiss A; Gianni L; Gao JJ; Stein A; Waldron-Lynch M; Heeson S; Beattie MS; Yoo B; Cortes J; Baselga J
Ann Oncol; 2017 Apr; 28(4):761-768. PubMed ID: 28057664
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.
Cargnin S; Shin JI; Genazzani AA; Nottegar A; Terrazzino S
Cancer Chemother Pharmacol; 2020 Nov; 86(5):577-588. PubMed ID: 33005979
[TBL] [Abstract][Full Text] [Related]
19. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]